site background
Skip to content
Ivy Brain Tumor Center
Trial EligibilityDonate
Main Menu
  • Physicians
  • Industry
  • Ivy Blog
Talk to an Ivy Navigator
  • The Challenge
    • Current Standard of Care
    • Conventional Clinical Trials
  • Clinical Trials
    • Current Trials
      • SONODYNAMIC THERAPY IN RECURRENT GLIOBLASTOMA
      • AZD1390 For Recurrent Grade IV Glioma
      • Sonodynamic Therapy in Recurrent High-Grade Glioma
      • Niraparib for Newly Diagnosed Glioblastoma
      • Pamiparib for newly diagnosed or recurrent glioblastoma
      • Abemaciclib Plus LY3214996 For Recurrent Glioblastoma
      • Sonodynamic Therapy in DIPG
      • Infigratinib in Recurrent Glioblastoma Patients
      • RIBOCICLIB FOR RECURRENT GLIOBLASTOMA
      • RIBOCICLIB FOR RECURRENT MENINGIOMA
    • What is a Phase 0 Trial?
    • Why Ivy Clinical Trials?
    • What We Treat
      • Gliomas
      • Brain Metastases
      • Meningiomas
      • Ependymomas
      • Craniopharyngiomas
      • Pineal-Region Tumors
  • Patients
    • Patient Stories
    • What to Expect
    • Planning Your Visit
      • Lodging
      • Transportation
    • Patient Support
    • FAQs
    • Share Your Story
  • Research
    • Scientific Cores
    • Laboratories
      • Mehta Laboratory
      • Tovmasyan Laboratory
      • Tien Laboratory
      • Mirzadeh Laboratory
    • Certifications
    • Preclinical Work
    • Industry Collaboration
    • Published Research
    • Ivy Center Seminar Series
  • About
    • Team
      • Administration
      • Business Operations
      • Clinical Operations
      • Communications
      • Preclinical and Translational Science
      • Clinicians
    • New Ivy Headquarters
    • It’s personal
    • Barrow Neurological Institute
    • The Ben and Catherine Ivy Foundation
    • Newsroom
    • Events
    • Donate
    • Careers
    • Contact Us
  • ESPAÑOL

Talk to an Ivy Navigator

602-406-8605
Home » About » Team » Artak Tovmasyan, PhD
Artak Tovmasyan
  • phone:(602) 406-5096
  • Send Email

Artak Tovmasyan, PhD

Pharmacokinetics Core Leader

Dr. Artak Tovmasyan received his PhD Degree in Pharmaceutical Sciences from the Yerevan State Medical University, Armenia. He then completed his postdoctoral studies in the Department of Radiation Oncology at Duke University Medical School. He has over 15 years of research experience in drug design and development in the field of free radical biology and medicine and in particular design of SOD mimics for anticancer therapy and radioprotection. His research resulted in 55 manuscripts published in peer-reviewed journals, and over 90 presentations and invited talks at national meetings and international conferences in the United States and outside. He has also co-authored several book chapters with J Wiley and Springer Publishing Companies and served as ad-hoc reviewer to numerous journals.

During his postdoctoral years at Duke University Dr. Tovmasyan was involved in the development of new redox-active metalloporphyrins with high SOD-like potency, low systemic toxicity and remarkable efficacy in oxidative stress related disorders, such as radiation injuries, cancer, CNS disorders, and diabetes. He has developed methods to evaluate the accumulation and distribution of SOD-mimics in targeted tissues/organs and studied the pharmacokinetic and toxicity profiles of the lead compounds. Dr. Tovmasyan has revealed the mechanisms involved in the therapeutic action of SOD mimics through detailed analyses of reaction kinetics and cellular redoxome/proteome by HPLC and LCMS/MS techniques.

Dr. Tovmasyan is a co-developer of an early generation SOD mimic, BMX-001, which is now in four Phase I/II Clinical Trials (NCT03386500, NCT03608020, NCT02990468, and NCT02655601; supported by STTR/NIH) as a radio-protector of normal tissues with glioma, head and neck, and anal cancer patients. Over the last two years he has further designed a new class of fluorinated metalloporphyrins of 4th generation with outstanding safety/toxicity profile and catalytic potency. The compounds are currently being tested in prostate cancer to reduce the radiation-induced normal tissue damage.

Dr. Tovmasyan holds co-authorship in 8 patents, patent applications, and invention disclosures. He is a Principal Investigator at the Ivy Brain Tumor Center.  As the leader of our Pharmacokinetic Program, Dr. Tovmasyan will be involved in the early-phase clinical trials and with his expertise in pharmaceutical sciences help identify the most effective therapies for brain tumor treatment. 

Arial shot of the Ivy Brain Tumor Center
Ivy Brain Tumor Center
  • The Challenge
    • Current Standard of Care
    • Conventional Clinical Trials
  • Phase 0 Clinical Trials
    • Why Ivy Clinical Trials?
    • What We Treat
    • Brain Tumor Clinical Trials
  • Patients
    • Patient Stories
    • What to Expect
    • Planning Your Visit
    • Patient Support
    • FAQs
  • About
    • Team
    • Barrow Neurological Institute
    • The Ben and Catherine Ivy Foundation
    • Newsroom
    • Events
    • Donate
    • Careers
    • Contact Us

Stay Updated

Follow Us

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube

2910 North Third Avenue
Phoenix, Arizona 85013
(602) 406-6489
[email protected]
Mailing Address for Donations »

© Ivy Brain Tumor Center, 2023. All Rights Reserved.
  • Privacy Policy
  • Site Map
Important Notice

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device.